LUCD (Lucid Diagnostics) FCF Margin %: -980.57% (As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.07
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics FCF Margin %?

Lucid Diagnostics LUCD +4.85% 26 FCF Margin % is -980.57% as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 94.48% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lucid Diagnostics's Free Cash Flow for the three months ended in Mar. 2026 was $-12.32 Mil. Lucid Diagnostics's Revenue for the three months ended in Mar. 2026 was $1.26 Mil. Therefore, Lucid Diagnostics's FCF Margin % for the quarter that ended in Mar. 2026 was -980.57%.

As of today, Lucid Diagnostics's current FCF Yield % is -22.54%.

The historical rank and industry rank for Lucid Diagnostics's FCF Margin % or its related term are showing as below:

LUCD' s FCF Margin % Range Over the Past 10 Years
Min: -8114.85   Med: -1360.71   Max: -904.56
Current: -904.56

During the past 7 years, the highest FCF Margin % of Lucid Diagnostics was -904.56%. The lowest was -8114.85%. And the median was -1360.71%.

LUCD's FCF Margin % is ranked worse than
94.48% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: -0.03 vs LUCD: -904.56

Lucid Diagnostics FCF Margin % Related Terms

Lucid Diagnostics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics FCF Margin % Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -3,706.00 -8,114.85 -1,360.71 -1,030.51 -991.97

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,516.67 -909.20 -901.82 -839.69 -980.57

LUCD vs TLSI, INFU, TANAF: FCF Margin % Comparison

For the Medical Devices subindustry, Lucid Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucid Diagnostics FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's FCF Margin % falls into.


LUCD
26GF Score
Lucid Diagnostics Inc LUCD
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lucid Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-46.682/4.706
=-991.97 %

Lucid Diagnostics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-12.316/1.256
=-980.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -980.57% mean?
Lucid Diagnostics (LUCD) has a FCF Margin % of -980.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lucid Diagnostics and its competitors. According to the industry distribution chart, Lucid Diagnostics ranks #770 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is Lucid Diagnostics' FCF Margin % too high?
Lucid Diagnostics' current FCF Margin % is -980.57%. Based on the distribution chart, Lucid Diagnostics ranks #770 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' FCF Margin % compare to TLSI and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #770 out of 815 companies for FCF Margin %. This places Lucid Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current FCF Margin % is -980.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current FCF Margin % is -980.57%. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current FCF Margin % is -980.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • FCF Margin %: -980.57%
  • GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$0.81
GF Value